DaVita Inc. (NYSE:DVA) Short Interest Update

DaVita Inc. (NYSE:DVA) saw a large drop in short interest during the month of November. As of November 15th, there was short interest totalling 3,900,000 shares, a drop of 8.9% from the October 31st total of 4,280,000 shares. Currently, 5.0% of the shares of the company are short sold. Based on an average daily volume of 814,700 shares, the short-interest ratio is currently 4.8 days.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Truist Financial raised their price objective on shares of DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a research note on Monday, October 7th. Barclays lifted their target price on shares of DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. UBS Group lifted their target price on shares of DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. Finally, Bank of America lifted their target price on shares of DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a research report on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, DaVita currently has an average rating of “Hold” and a consensus target price of $161.80.

DaVita Trading Down 0.9 %

Shares of NYSE:DVA traded down $1.45 during trading on Monday, reaching $164.72. The stock had a trading volume of 180,823 shares, compared to its average volume of 818,140. The business has a fifty day moving average price of $158.57 and a 200-day moving average price of $149.48. The company has a quick ratio of 1.33, a current ratio of 1.37 and a debt-to-equity ratio of 15.78. The stock has a market cap of $13.51 billion, a P/E ratio of 17.93, a PEG ratio of 0.94 and a beta of 0.89. DaVita has a fifty-two week low of $103.40 and a fifty-two week high of $169.51.

DaVita (NYSE:DVA) last posted its quarterly earnings data on Tuesday, October 29th. The company reported $2.59 earnings per share for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). DaVita had a net margin of 6.53% and a return on equity of 88.18%. The firm had revenue of $3.26 billion during the quarter, compared to analyst estimates of $3.25 billion. During the same period in the prior year, the firm earned $2.85 EPS. The business’s quarterly revenue was up 4.6% on a year-over-year basis. As a group, analysts anticipate that DaVita will post 9.71 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Javier Rodriguez sold 50,000 shares of DaVita stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $165.05, for a total value of $8,252,500.00. Following the sale, the chief executive officer now owns 837,835 shares of the company’s stock, valued at $138,284,666.75. The trade was a 5.63 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On DaVita

Institutional investors have recently bought and sold shares of the stock. Transcendent Capital Group LLC purchased a new stake in DaVita during the third quarter worth approximately $25,000. Blue Trust Inc. lifted its stake in shares of DaVita by 58.6% in the second quarter. Blue Trust Inc. now owns 211 shares of the company’s stock worth $29,000 after acquiring an additional 78 shares in the last quarter. Family Firm Inc. acquired a new stake in DaVita during the 2nd quarter valued at approximately $43,000. Versant Capital Management Inc grew its stake in DaVita by 90.6% during the 2nd quarter. Versant Capital Management Inc now owns 326 shares of the company’s stock valued at $45,000 after purchasing an additional 155 shares in the last quarter. Finally, Friedenthal Financial acquired a new stake in DaVita during the 2nd quarter valued at approximately $48,000. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.